Additionally, considering the role of VEGF in the regulation of these aberrant fenestrations in tumors, VEGF inhibition has also been explored as a therapeutic target for cancer, resulting in various FDA-approved drugs, such as Axitinib (Inlyta®), Bevacizumab (Avastin®), and Cabozantinib (Cometriq®) [33]. Here, VEGFA is linked to cancer.